Illumina launches new kits for targeted resequencing studies

Illumina, Inc. (NASDAQ: ILMN) today introduced Nextera Exome and Custom Enrichment kits, the Company's latest targeted resequencing solutions offering sample preparation and enrichment in a single, integrated workflow. Leveraging the speed of Nextera technology and supporting the industry's lowest DNA sample input requirements (50 ng), the new kits enable researchers to quickly and economically perform a wide range of studies - from small, focused gene panels to full human exomes.    

Upfront sample preparation is an often difficult and time-consuming task for targeted resequencing studies. Nextera Exome and Custom Enrichment kits replace the lengthy sample preparation protocols with a single, streamlined workflow that can be performed in less than three hours and removes the requirement for mechanical DNA fragmentation. The kits integrate the ease of Nextera sample preparation with the company's established TruSeq® Exome and Custom Enrichment solutions for a fast, scalable and highly efficient approach to targeted resequencing. Offering excellent data quality with a low DNA sample input requirement, the kits enable researchers to study small samples, while retaining sufficient material for future analysis.

"Nextera Enrichment kits deliver superior performance on all fronts with a simple, rapid workflow that eliminates almost an entire day of preparation time," said Christian Henry, Senior Vice President and General Manager, Genomic Solutions. "Developed, tested, and optimized for Illumina sequencing platforms, Nextera Enrichment kits make targeted resequencing more broadly available to researchers who are interested in performing studies on DNA samples that may only be available in limited quantities."

"The combination of Nextera library prep and TruSeq capture produces a simple workflow and high quality data. It will allow us to process large numbers of samples without investing in automation systems and opens up capture-based sequencing to samples that would not have been accessible due to DNA input constraints," said Dr. James Hadfield, Head of Genomics, Cancer Research, UK. "We have been able to perform custom and exome capture as well as low coverage genome sequencing from the same 50 ng input DNA."

Nextera Exome Enrichment kits offer:

  • Comprehensive coverage of the human exome, with greater than 62 Mb of both coding regions and untranslated regions (UTRs).
  • Excellent data quality with high enrichment rates and premier coverage uniformity.
  • The ability to fully customize content with Illumina's DesignStudio, a free online tool for Illumina customers.
  • Industry-best DNA input of 50 ng.
  • A unique 12-plex pre-enrichment sample pooling, reducing hands-on time and enabling the most cost-effective and operationally efficient workflow.
Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Illumina, Inc.. (2019, June 19). Illumina launches new kits for targeted resequencing studies. News-Medical. Retrieved on October 31, 2024 from https://www.news-medical.net/news/20120717/Illumina-launches-new-kits-for-targeted-resequencing-studies.aspx.

  • MLA

    Illumina, Inc.. "Illumina launches new kits for targeted resequencing studies". News-Medical. 31 October 2024. <https://www.news-medical.net/news/20120717/Illumina-launches-new-kits-for-targeted-resequencing-studies.aspx>.

  • Chicago

    Illumina, Inc.. "Illumina launches new kits for targeted resequencing studies". News-Medical. https://www.news-medical.net/news/20120717/Illumina-launches-new-kits-for-targeted-resequencing-studies.aspx. (accessed October 31, 2024).

  • Harvard

    Illumina, Inc.. 2019. Illumina launches new kits for targeted resequencing studies. News-Medical, viewed 31 October 2024, https://www.news-medical.net/news/20120717/Illumina-launches-new-kits-for-targeted-resequencing-studies.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Illumina launches its first product enabling long- and short-read sequencing on one instrument